Welcome to our dedicated page for Inspira Technologies Oxy Bhn SEC filings (Ticker: IINN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inspira Technologies Oxy B.H.N. Ltd. filings document foreign-private-issuer current reports, shareholder meeting materials and registration statement incorporation for its technology business. Form 6-K reports furnish press releases on AME system orders, commercial deployments, the QTREX platform, cryogenic interconnect development and shareholder communications, while proxy materials cover voting matters such as amendments to the company's articles of association.
Other filings describe governance and officer appointments, ordinary-share voting procedures, Form F-3 and Form S-8 registration statement references, and capital-structure context tied to the company's Nasdaq-listed securities and medical technology operations.
Yafit Tehila reported a proposed sale of 30,000 Ordinary Shares. The filing shows a sale date of 05/27/2026 for 30,000 shares with proceeds listed as $60,561.18.
The record also notes 86,395 shares issued upon vesting of RSUs on 11/02/2021. The notice was submitted using broker-dealer Oppenheimer & Co. Inc.
Quantum Ltd. submitted a Form 144 notice for the proposed sale of 30,000 Ordinary Shares through Oppenheimer & Co. Inc. on 05/27/2026 on Nasdaq. The filing lists prior acquisitions including 13,605 shares acquired upon exercise of employee stock options on 05/27/2026 (cash payment upon exercise) and 86,395 shares issued upon vesting of RSUs on 11/02/2021.
Qtrex Quantum Ltd. reports audited abbreviated financials and unaudited pro forma statements related to its acquisition of Nano Dimension’s Additively Manufactured Electronics and Fabrica product lines. The acquired business generated $5.5 million in 2025 revenue but had a $17.4 million shortfall of revenues over direct expenses and recurring losses, leading auditors to highlight substantial doubt about its ability to continue as a going concern without support from Qtrex. Pro forma 2025 figures combine Qtrex and the acquired operations, showing higher revenue but a larger net loss, illustrating the initial impact of integrating these 3D-printing electronics businesses.
Qtrex Quantum Ltd., formerly Inspira Technologies Oxy B.H.N. Ltd., reports that shareholders approved a corporate name change, which became effective on May 10, 2026 with the Israeli Registrar of Companies. The company plans to begin trading on the Nasdaq Capital Market under the new ticker symbol “QTEX” for its ordinary shares and “QTEXW” for its warrants at the opening of trading on May 20, 2026, replacing “IINN” and “IINNW.” The filing emphasizes that the name and ticker changes do not alter shareholder rights, company status, or the validity and transferability of existing share certificates, and no shareholder action is required. The accompanying press release explains that the new name highlights a strategic focus on the company’s Additively Manufactured Electronics platform for advanced manufacturing, high-performance electronics, and quantum connectivity, while it continues to develop and monetize parts of its medical technology portfolio.
Inspira Technologies Oxy B.H.N. Ltd. furnished a report highlighting a new commercial milestone for its ART100 system. NYU Langone Hospital in New York City issued a $580,000 purchase order for Inspira’s FDA-cleared ART100 extracorporeal blood circulation systems following a multi-patient hospital evaluation.
The evaluation involved using ART100 in the treatment of more than 30 patients across varied cardiopulmonary and surgical cases, giving NYU Langone operational experience with the platform and leading to its decision to move from clinical assessment to commercial procurement. Inspira notes that this order provides an important hospital reference as it continues commercial discussions with additional U.S. and international hospitals and pursues an active strategic process involving potential transactions related to the ART100 system and other medical assets.
Inspira Technologies OXY B.H.N. Ltd files an amendment to its Schedule 13G/A reporting that Joe Ronen Hayon beneficially owns 2,544,474 ordinary shares, equal to 5.7% of the company's outstanding ordinary shares. The filing states the ownership comprises 656,081 ordinary shares and 1,888,393 ordinary shares vested pursuant to issued and outstanding restricted stock units. The percentage is calculated on 44,473,260 outstanding shares. The signature block shows the amendment was signed on 05/15/2026.
INSPIRA TECHNOLOGIES OXY B.H.N. LTD. reports that Armistice Capital, LLC and Steven Boyd collectively beneficially own 4,343,252 ordinary shares, representing 9.99% of the outstanding ordinary shares. The filing states Armistice Capital exercises shared voting and dispositive power over those shares under an Investment Management Agreement.
Inspira Technologies is reshaping its strategy around three value tracks: a commercially active Additively Manufactured Electronics (AME) platform, a focused quantum connectivity program, and a repositioned medical business. Management expects recent commercial activity to mark the start of a broader revenue ramp supported by AME system sales, recurring consumables and service revenues, and monetization of medical technologies.
The Company reports more than $1 million from recent AME-related transactions, with most already received in cash, early deployments at a Tier-1 U.S. defense customer and a “Magnificent Seven” technology company, and a joint development agreement with Qarakal Quantum to validate its monolithic quantum connectivity architecture. The medical segment is being prepared for partial sale, backed by FDA-cleared ART100 usage in over 40 patients and planned FDA submission for the HYLA platform, with a goal of reaching at least a term sheet by the end of the third quarter of 2026.
Inspira is also moving to change its name to QTREX Quantum Ltd., has reduced medical business burn, terminated its ATM and SEPA facilities in March 2026, and emphasizes disciplined capital allocation aimed at preserving cash, extending runway, and translating strategic progress into measurable financial results.
Inspira Technologies Oxy B.H.N. Ltd. held an Extraordinary General Meeting of Shareholders on May 6, 2026. The meeting was initially adjourned at 12:00 p.m. Israel time for lack of quorum but reconvened at 1:30 p.m., when a quorum was present.
At the adjourned meeting, shareholders approved the single agenda item described in the company’s earlier notice and proxy statement filed on April 16, 2026. The company also states that this report is incorporated by reference into its existing registration statements on Forms F-3 and S-8.
Inspira Technologies Oxy B.H.N. Ltd. secured a $596,000 purchase order for an Additively Manufactured Electronics (AME) system from a leading Irish technological research university. The order includes a non-refundable 40% upfront payment, already received, with the remainder due on delivery.
The AME installation is expected to generate recurring revenue from proprietary consumables, wear parts, and annual service fees over the system’s lifetime. Inspira plans to deliver and deploy the system in the coming weeks, using this site as a potential reference installation for further academic and commercial engagements in Europe and beyond.